Clinical Trial Update: Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety, tolerability, and immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) given as a two-dose regimen. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Pneumovax 23 (Pneumococcal polysaccharide vaccine 23-valent)
• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Pneumococcal Vaccines | Phase 3 | Status: COMPLETED | Results posted: 2011-05-09